AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy
— 94% manufacturing success rate achieved for personalized cancer immunotherapy development — IRVINE, Calif., Nov. 2, 2020 /PRNewswire/ — AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell applications, announced today that treatment has been completed for all 57 patients in the Phase 2 clinical trial of AV-GBM-1 in patients with glioblastoma. The … Continued